Immunotherapy is a critical and essential component of cancer care. However, its effectiveness differs from patient to patient. Moreover, there has been a constant debate on the implications of immunotherapy for cancer patients. Benign prostatic hyperplasia (BPH) is a common disease that affects men 50 years of age and above. Surgery is a commonly used treatment; however, significant advances in the medical field have opened pharmaceutical interventions to treat BPH.
Chronic kidney disease (CKD) is a serious and progressive condition associated with significant patient morbidity. Despite various interventions, kidney failure has also been a common outcome of CKD. Recently, SGLT2 inhibitors have been shown to slow down the progression of CKD. Join our exclusive webinar on “Immunotherapy, Benign Prostatic Hyperplasia, and Kidney Disease Management” with our experts on 29 th August 2024…
